Biodesix Announces Presentation on Use of Biomarker-Based Risk Assessment to Inform Lung Nodule Management

Author's Avatar
Apr 22, 2021

Biodesix%2C+Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced a webinar to discuss biomarkers and risk assessment in lung nodule management. The virtual session, hosted by the American College of Chest Physicians® (CHEST) and led by Susan Garwood, MD, National Physician Director of Pulmonary Disease at HCA Healthcare, is titled, “Using biomarker-based risk assessment to inform lung nodule referral decisions” and scheduled for 2:30 p.m. CT on Monday, April 26, 2021. Participants are encouraged to register using the following Zoom registration link: https%3A%2F%2Fchestnet.zoom.us%2Fwebinar%2Fregister%2FWN_CTVW3JGRSFKg0d1OLLzGdw